Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.

Cancer science - 1 May 2015

Takahashi Naoki, Yamada Yasuhide, Furuta Koh, Nagashima Kengo, Kubo Akiko, Sasaki Yusuke, Shoji Hirokazu, Honma Yoshitaka, Iwasa Satoru, Okita Natsuko, Takashima Atsuo, Kato Ken, Hamaguchi Tetsuya, Shimada Yasuhiro

Abstract excerpt

Skin toxicity is a known clinical signature used to predict the prognosis of anti-epidermal growth factor receptor (EGFR) antibody treatment in metastatic colorectal cancer (mCRC). There are no biological markers to predict skin toxicity before anti-EGFR antibody treatment in mCRC patients. Between August 2008 and August 2011, pretreatment serum samples were obtained from KRAS wild-type (WT) patients who received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to Hepatocyte Growth Factor

Share to Insulin-Like Growth Factor I

Share to Panitumumab

Share to Transforming Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 25707609
DOI: 10.1111/cas.12642
PMCID: PMC4452162

Genes

EGFR
AREG
EREG
HGF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.PMID 25707609Read ↗

Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.Semantic proximity Read ↗

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.Semantic proximity Read ↗

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.Semantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].Semantic proximity Read ↗

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.Semantic proximity Read ↗

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.Semantic proximity Read ↗

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.Semantic proximity Read ↗

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).Semantic proximity Read ↗

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.Semantic proximity Read ↗

Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis.Semantic proximity Read ↗

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.